Status:
ACTIVE_NOT_RECRUITING
Optimization of a Decision Formula for Optimal Timing of Immunosuppressive Therapy Initiation in Primary Membranous Nephropathy: A Multicenter Retrospective Cohort Study
Lead Sponsor:
Yipeng Liu
Collaborating Sponsors:
Peking University First Hospital
Conditions:
Primary Membranous Nephropathy
Eligibility:
All Genders
Brief Summary
The goal of this observational study is to optimize the evaluation formula for the timing of initiating immunosuppressive therapy in primary membranous nephropathy in patients with primary membranous ...
Eligibility Criteria
Inclusion
- It meets one of the diagnostic criteria for PMN as stipulated in the KDIGO 2021 Clinical Practice Guidelines for the Management of Glomerular Diseases: patients with a clear diagnosis of PMN based on renal biopsy pathology or presenting with nephrotic syndrome and positive anti-PLA2R antibody detection (\>14RU/mL), and excluding secondary factors such as tumors, infections, drugs, and systemic autoimmune diseases.
Exclusion
- (1) Patients who have received treatment with immunosuppressive medications other than oral prednisolone.
- (2) The time interval between the renal biopsy and the baseline measurement is longer than 3 years.
- (3) Initiate the use of immunosuppressive agents within 1 week after the diagnosis of PMN.
- (4) Participate in the immunosuppressive treatment trial during the follow-up period and be in the intervention group.
Key Trial Info
Start Date :
January 1 1990
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2025
Estimated Enrollment :
282 Patients enrolled
Trial Details
Trial ID
NCT06924476
Start Date
January 1 1990
End Date
September 30 2025
Last Update
April 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qianfoshan Hospital
Jinan, Shandong, China, 250000